Morgan Stanley Lowers Bruker (BRKR) Price Target to $32.00

Bruker (NASDAQ:BRKR) had its price objective trimmed by Morgan Stanley from $35.00 to $32.00 in a research note published on Friday morning. The firm currently has an equal weight rating on the medical research company’s stock.

A number of other equities research analysts also recently issued reports on the company. Leerink Swann upped their price objective on Bruker from $32.00 to $34.00 and gave the company a market perform rating in a research report on Friday. BidaskClub downgraded Bruker from a strong-buy rating to a buy rating in a report on Thursday, January 11th. Zacks Investment Research downgraded Bruker from a buy rating to a hold rating in a report on Tuesday, January 9th. BTIG Research started coverage on Bruker in a report on Friday, January 5th. They issued a buy rating and a $42.00 price target on the stock. Finally, Evercore ISI started coverage on Bruker in a report on Wednesday, January 3rd. They issued an in-line rating and a $36.00 price target on the stock. Two investment analysts have rated the stock with a sell rating, twelve have issued a hold rating and four have issued a buy rating to the company. The company currently has a consensus rating of Hold and a consensus price target of $32.29.

Shares of Bruker (NASDAQ:BRKR) traded down $1.03 during mid-day trading on Friday, reaching $30.59. The company’s stock had a trading volume of 1,340,000 shares, compared to its average volume of 525,080. Bruker has a fifty-two week low of $21.83 and a fifty-two week high of $36.53. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.60 and a current ratio of 2.60. The stock has a market capitalization of $4,918.89, a P/E ratio of 62.43, a PEG ratio of 2.34 and a beta of 1.05.

Bruker (NASDAQ:BRKR) last issued its quarterly earnings data on Thursday, February 8th. The medical research company reported $0.51 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.49 by $0.02. Bruker had a return on equity of 26.58% and a net margin of 4.45%. The business had revenue of $530.50 million for the quarter, compared to the consensus estimate of $506.74 million. During the same period in the prior year, the business posted $0.46 earnings per share. The company’s quarterly revenue was up 12.8% compared to the same quarter last year. equities research analysts expect that Bruker will post 1.34 earnings per share for the current fiscal year.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Arrowstreet Capital Limited Partnership increased its holdings in Bruker by 34.2% during the 4th quarter. Arrowstreet Capital Limited Partnership now owns 476,524 shares of the medical research company’s stock worth $16,354,000 after purchasing an additional 121,410 shares during the period. UBS Asset Management Americas Inc. increased its holdings in Bruker by 3.4% during the 4th quarter. UBS Asset Management Americas Inc. now owns 98,571 shares of the medical research company’s stock worth $3,383,000 after purchasing an additional 3,262 shares during the period. BlackRock Inc. increased its holdings in Bruker by 7.1% during the 4th quarter. BlackRock Inc. now owns 5,173,860 shares of the medical research company’s stock worth $177,566,000 after purchasing an additional 341,389 shares during the period. First Trust Advisors LP increased its holdings in Bruker by 3.5% during the 4th quarter. First Trust Advisors LP now owns 519,818 shares of the medical research company’s stock worth $17,840,000 after purchasing an additional 17,659 shares during the period. Finally, Swiss National Bank increased its holdings in Bruker by 1.6% during the 4th quarter. Swiss National Bank now owns 188,800 shares of the medical research company’s stock worth $6,480,000 after purchasing an additional 2,900 shares during the period. Institutional investors own 65.63% of the company’s stock.

WARNING: This story was posted by Community Financial News and is the sole property of of Community Financial News. If you are viewing this story on another domain, it was stolen and reposted in violation of United States and international trademark and copyright laws. The original version of this story can be accessed at https://www.com-unik.info/2018/02/10/morgan-stanley-lowers-bruker-brkr-price-target-to-32-00.html.

About Bruker

Bruker Corporation designs and manufactures scientific instruments, and analytical and diagnostic solutions. Its segments include the Bruker BioSpin Group; the Bruker Chemicals, Applied Markets, Life Science, In-Vitro Diagnostics, Detection (CALID) Group; the Bruker Nano Group, and the Bruker Energy & Supercon Technologies (BEST) Segment.

Analyst Recommendations for Bruker (NASDAQ:BRKR)

Receive News & Ratings for Bruker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bruker and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit